




ApoScreen® Annexin V

Cat. No.	Format	Size
10040-01	Purified (UNLB)	0.1 mg
10040-02	Fluorescein (FITC)	100 tests
10040-08	Biotin (BIOT)	100 tests
10040-09	R-phycoerythrin (PE)	100 tests
10040-11	Allophycocyanin (APC)	100 tests
10040-15	Cyanine 5 (CY5)	100 tests



Day old BALB/c mouse bone marrow cells were stained with Annexin V-CY5 (SB Cat. No. 10040-15) with and without Propidium Iodide (SB Cat. No. 10044-01).

Description

ApoScreen® Annexin V (SB Cat. No. 10040) is a recombinant protein that is expressed in *E. coli*. A number of changes in cell structure occur during apoptosis. One major change is the loss of membrane phospholipid asymmetry, with translocation of phosphatidylserine (PS) from the inner leaflet of the phospholipid bilayer to the external surface. Annexin V, a member of the annexin family of calcium-dependent phospholipid binding proteins, has a high affinity for phosphatidylserine (PS)-containing phospholipid bilayers. Conjugated Annexin V can be used to monitor changes in cell membrane phospholipid asymmetry, thereby providing a convenient tool for detection of apoptotic cells.

Applications

FC – Quality tested¹⁻²⁵
 IHC-WM – Reported in literature²⁶
 ICC – Reported in literature^{6,27}

Working Dilutions

Flow Cytometry	FITC, BIOT, PE, APC, and CY5 conjugates	10 μ L/10 ⁶ cells
	For flow cytometry, the suggested use of these reagents is in a final volume of 100 μ L of ApoScreen® Annexin Binding Buffer (SB Cat. No. 10045-01)	
Other Applications	Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.	

Suggested Staining Protocol

- Wash cells twice in cold PBS
- Resuspend cells in cold 1X ApoScreen® Annexin Binding Buffer (SB Cat. No. 10045-01) to a concentration of 1 x 10⁶ cells/mL
- Add 100 μ L of cell suspension to 5 mL polystyrene round bottom tubes
- Add 10 μ L of conjugated ApoScreen® Annexin V
- Gently vortex each tube and incubate for 15 minutes at 2-8°C and protected from light
- Without washing, add ~380 μ L of cold 1X ApoScreen® Annexin Binding Buffer to each tube
- Add 10 μ L of ApoScreen® 7-Aminoactinomycin D (7-AAD; SB Cat. No. 10042-01) or ApoScreen® Propidium Iodide (PI; SB Cat. No. 10044-01)
- Analyze by flow cytometry immediately

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA Mailing Address: P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • Fax: 205.945.8768

Email: info@southernbiotech.com • Website: www.southernbiotech.com

Handling and Storage

- The purified (UNLB) ApoScreen[®] Annexin V is supplied as 0.1 mg of purified recombinant protein lyophilized from PBS. Store material at -20°C prior to reconstitution. Reconstitute with 1.0 mL of dH₂O. Store reconstituted material at 2-8°C.
- The fluorescein (FITC), biotin (BIOT), and Cyanine 5 (CY5) ApoScreen[®] Annexin V conjugates are supplied as 100 tests in 1.0 mL of ApoScreen[®] Annexin V Binding Buffer. Store at 2-8°C.
- The R-phycoerythrin (PE) and allophycocyanin (APC) ApoScreen[®] Annexin V conjugates are supplied as 100 tests in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific (M)SDS.

References

1. Gao-Uozumi C, Uozumi N, Miyoshi E, Nagai K, Ikeda Y, Teshima T, et al. A novel carbohydrate binding activity of annexin V toward a bisecting N-acetylglucosamine. *Glycobiology*. 2000;10:1209-16. (FC)
2. Rademaekers A, Kölsch E, Specht C. T cell mediated antibody invariance in an immune response against a bacterial carbohydrate antigen requires CD28/B7-1 costimulation. *Dev Immunol*. 2001;8:243-57. (FC)
3. Kunz-Schughart LA, Schroeder JA, Wondrak M, van Rey F, Lehle K, Hofstaedter F, et al. Potential of fibroblasts to regulate the formation of three-dimensional vessel-like structures from endothelial cells in vitro. *Am J Physiol Cell Physiol*. 2006;290:C1385-98. (FC)
4. Woolf E, Brenner O, Goldenberg D, Levanon D, Groner Y. Runx3 regulates dendritic epidermal T cell development. *Dev Biol*. 2007;303:703-14. (FC)
5. Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. *Blood*. 2008;111:1584-93. (FC)
6. Reif RD, Martinez MM, Wang K, Pappas D. Simultaneous cell capture and induction of apoptosis using an anti-CD95 affinity microdevice. *Anal Bioanal Chem*. 2009;395:787-95. (FC, ICC)
7. de Medina P, Payré B, Boubekeur N, Bertrand-Michel J, Tercé F, Silvente-Poirot S, et al. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism. *Cell Death Differ*. 2009;16:1372-84. (FC)
8. Siegers GM, Dhamko H, Wang X, Mathieson AM, Kosaka Y, Felizardo TC, et al. Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. *Cytotherapy*. 2011;13:753-64. (FC)
9. Eckermann CW, Lehle K, Schmid SA, Wheatley DN, Kunz-Schughart LA. Characterization and modulation of fibroblast/endothelial cell co-cultures for the in vitro preformation of three-dimensional tubular networks. *Cell Biol Int*. 2011;35:1097-110. (FC)
10. Alberter B, Vogel B, Lengenfelder D, Full F, Ensser A. Genome-wide histone acetylation profiling of Herpesvirus saimiri in human T cells upon induction with a histone deacetylase inhibitor. *J Virol*. 2011;85:5456-64. (FC)
11. Gottlieb Y, Topaz O, Cohen LA, Yakov LD, Haber T, Morgenstern A, et al. Physiologically aged red blood cells undergo erythrophagocytosis in vivo but not in vitro. *Haematologica*. 2012;97:994-1002. (FC)
12. Di Pardo A, Amico E, Favellato M, Castrataro R, Fucile S, Squitieri F, et al. FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. *Hum Mol Genet*. 2014;23:2251-65. (FC)
13. Liyanage NP, Dassanayake RP, Kuszyński CA, Duhamel GE. Contribution of Helicobacter hepaticus cytolethal distending toxin subunits to human epithelial cell cycle arrest and apoptotic death in vitro. *Helicobacter*. 2013;18:433-43. (FC)
14. Jenks SA, Palmer E, Marin E, Hartson L, Chida AS, Richardson C, et al. 9G4+ autoantibodies are an important source of apoptotic cell reactivity associated with high levels of disease activity in systemic lupus erythematosus. *Arthritis Rheum*. 2013;65:3165-75. (FC)
15. Vogel B, Tennert K, Full F, Ensser A. Efficient generation of human natural killer cell lines by viral transformation. *Leukemia*. 2014;28:192-5. (FC)
16. Huang S, Wu B, Li D, Zhou W, Deng G, Zhang K, et al. Knockdown of astrocyte elevated gene-1 inhibits tumor growth and modifies microRNAs expression profiles in human colorectal cancer cells. *Biochem Biophys Res Commun*. 2014;444:338-45. (FC)
17. Peres RS, Liew FY, Talbot J, Carregaro V, Oliveira RD, Almeida SL, et al. Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis. *Proc Natl Acad Sci USA*. 2015;112:2509-14. (FC)
18. Meng Q, Wang H, Song Z, Shan Z, Yuan Z, Zheng Q, et al. Overexpression of NDC80 is correlated with prognosis of pancreatic cancer and regulates cell proliferation. *Am J Cancer Res*. 2015;5:1730-40. (FC)
19. Koh DW, Powell DP, Blake SD, Hoffman JL, Hopkins MM, Feng X. Enhanced cytotoxicity in triple-negative and estrogen receptor-positive breast adenocarcinoma cells due to inhibition of the transient receptor potential melastatin-2 channel. *Oncol Rep*. 2015;34:1589-98. (FC)
20. Jia A, Lv Y, Guo X, Ren L, Qin J. Ectopic expression of p33^{ING1b} suppresses proliferation and induces apoptosis in colonic adenocarcinoma cells. *Oncol Lett*. 2015;10:1517-22. (FC)
21. Squitieri F, Di Pardo A, Favellato M, Amico E, Maglione V, Frati L. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. *J Cell Mol Med*. 2015;19:2540-8. (FC)
22. Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A. Latent membrane protein LMP2A impairs recognition of EBV-infected cells by CD8+ T cells. *PLoS Pathog*. 2015;11(6):e1004906. (FC)
23. Meusch U, Klingner M, Mathar C, Malysheva O, Baerwald C, Rossol M, et al. Brief report: Autocrine cytokine-mediated deficiency of TRAIL-induced monocyte apoptosis in rheumatoid arthritis. *Arthritis Rheumatol*. 2015;67:1760-5. (FC)
24. Batra SA, Shanthalingam S, Munske GR, Raghavan B, Kugadas A, Bavanthasivam J, et al. Acylation enhances, but is not required for, the cytotoxic activity of Mannheimia haemolytica leukotoxin in highborn sheep. *Infect Immun*. 2015;83:3982-8. (FC)
25. Betancourt D, Ramos JC, Barber GN. Retargeting oncolytic vesicular stomatitis virus to human T-cell lymphotropic virus type 1-associated adult T-cell leukemia. *J Virol*. 2015;89:11786-800. (FC)
26. Bourges J, Valamanesh F, Torriglia A, Jeanny J, Savoldelli M, Renard G, et al. Cornea graft endothelial cells undergo apoptosis by way of an alternate (caspase-independent) pathway. *Transplantation*. 2004;78:316-23. (IHC-WMM)
27. Polak MB, Valamanesh F, Felt O, Torriglia A, Jeanny J, Bourges J, et al. Controlled delivery of 5-chlorouracil using poly(ortho esters) in filtering surgery for glaucoma. *Invest Ophthalmol Vis Sci*. 2008;49:2993-3003. (ICC)

ApoScreen[®] is a registered trademark of Southern Biotechnology Associates, Inc.
Cy[®] is a registered trademark of GE Healthcare.

TB10040
16-Feb-16